Safety Profile of Maraviroc in Patients Coinfected With HIV-1 and Hepatitis B or C Included in the Maraviroc Expanded Access Program

HIV Clinical Trials, 04/24/2012

Maraviroc plus an optimized background therapy (OBT) did not increase the incidence of AEs or severe laboratory liver abnormalities in HIV–1–infected patients coinfected with hepatitis B virus (HBV) or hepatitis C virus (HCV).

Print Article Summary Cat 2 CME Report